KAVI-Institute of Clinical Research (KAVI-ICR) continues to demonstrate leadership in laboratory biosafety and biosecurity through its participation in the CEPI ISO 35001 Implementation Project. Representatives from KAVI-ICR, including its founder, Professor Omu Anzala, and Laboratory Technologist Dennis Chalo, attended a high-level coordination meeting at the National Institute for Communicable Diseases in Johannesburg from March 30 to April 1, 2026.

KAVI-Institute of Clinical Research is proud to highlight the participation of our Postdoctoral Research Fellow, Dr Zipporah Richard, in the One Health Early Career Champions Programme held in Helsinki, Finland.

The KAVI-Institute of Clinical Research (KAVI-ICR) recently visited the Microsoft AI for Good Lab in Nairobi. The meeting provided an opportunity to exchange ideas at the intersection of artificial intelligence and public health research and to understand each other’s work better.

KAVI-ICR hosted Dr Huwaida Bulhan, Africa Region Lead at Sanofi, for a courtesy visit focused on strengthening academia–industry collaboration.

The KAVI-Institute of Clinical Research (KAVI-ICR) is proud to announce that Project SeriHealth, a collaborative initiative with Silk Origin Limited, has been awarded 2nd place at the University of Nairobi Research Innovation Week Awards in the Innovations and Industrial Linkages category.

KAVI-Institute of Clinical Research (KAVI-ICR) is proud to share insights from AfriBOP 2026, held from 16–20 March in Cape Town, which celebrated a decade of transformative impact in building Africa’s research capacity.

From 10–12 March 2026, researchers from KAVI-Institute of Clinical Research (KAVI-ICR) actively participated in the HIV Vaccine Science Academy held in Dar es Salaam, Tanzania. The academy, organized by the International AIDS Society, brought together early-career scientists and leading global experts to explore the latest advances in HIV vaccine research.

As the world marks World Tuberculosis Day on March 24th, KAVI-Institute of Clinical Research reaffirms its commitment to raising awareness, promoting early diagnosis, and supporting effective treatment of tuberculosis (TB). Tuberculosis remains one of the world’s deadliest infectious diseases, with millions of new cases reported annually. Despite progress, global reductions in TB incidence remain below targets, highlighting the urgent need for intensified action.

Congratulations to the Director KAVI-ICR, Dr Marianne Mureithi, on being selected for the WomenLift Health 2026 East Africa Leadership Journey!

Among 60 outstanding women leaders across East Africa, Marianne Mureithi will spend the next 12 months deepening her leadership practice through a program intentionally designed for the complex realities of global public health today.

At KAVI-ICR, we are committed to championing women leaders who are driving change in health, and Marianne Mureithi exemplifies that every day.

Dr Marianne W. Mureithi, Director of the KAVI-Institute of Clinical Research (KAVI-ICR)  at the University of Nairobi, is a Co-Investigator on a newly announced CAD 2 million (5-year) international team grant funded by the Canadian Institutes of Health Research (CIHR) under its Bringing Biology to Cancer Prevention programme.

The study will examine how inflammation and hormonal changes influence HPV persistence and cervical cancer risk in menopausal women.